Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Generated: May 28, 2017
What are the generic drug sources for regadenoson and what is the scope of regadenoson freedom to operate?
Regadenoson is the generic ingredient in one branded drug marketed by Astellas and is included in one NDA. There are eighteen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.| Tradenames: | 1 |
| Patents: | 18 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: see list | 7 |
| Suppliers / Packagers: see list | 1 |
| Bulk Api Vendors: see list | 25 |
| Clinical Trials: see list | 39 |
| Patent Applications: see list | 74 |
| Drug Prices: | see low prices |
| DailyMed Link: | regadenoson at DailyMed |
| Drug Class | Adenosine Receptor Agonist |
| Mechanism of Action | Adenosine Receptor Agonists |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | RX | Yes | Yes | 7,683,037 | ► Subscribe | ► Subscribe | ||||||||||||||||||
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | RX | Yes | Yes | 8,470,801 | ► Subscribe | ► Subscribe | ||||||||||||||||||
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | RX | Yes | Yes | 7,183,264 | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | RX | Yes | Yes | ► Subscribe | ► Subscribe | |||||||||||||||||||
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | RX | Yes | Yes | 8,536,150 | ► Subscribe | ► Subscribe | ||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Expired Orange Book Patents
Available with subscription
Paragraph IV Activity
Available with subscription
Patent Maintenance
Available with subscription
Non-Orange Book Patents
Available with subscription
International Patents
Available with subscription
Supplementary Protection Certificates
Available with subscription
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639
Follow DrugPatentWatch:
